Visible Genetics, Inc.
This article was originally published in The Gray Sheet
Genotyping kits for hepatitis B and C will be available for research use on VGI's OpenGene DNA sequencing system early in 2002, the firm predicts. The Toronto firm gained 510(k) clearance for its Trugene HIV-1 genotyping kit for use with the system on Sept. 26 (1"The Gray Sheet" Sept. 3, 2001, p. 10). The first HIV drug-resistance test available in the U.S., the test includes software to aid in antiretroviral drug selection. The hepatitis tests will tell physicians which variant of hepatitis B or C is afflicting the patient
You may also be interested in...
Visible Genetics, Inc.(VGI) is confident that the clinical data for the company's Trugene HIV-1 genotyping test meets the standards set forth in an August FDA Center for Biologics Evaluation and Research (CBER) special controls draft guidance for in vitro HIV drug resistance genotype assays.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.